Abstract. Primary small cell carcinoma of the breast is a rare tumor of which less than 40 cases have been reported in the literature. Because of its rarity, its biological and clinical characteristics are still not fully understood and, to date, no standard therapy has been developed. Here, we present a case and a review of the literature regarding this cancer, focusing on clinicopathological findings and treatment. Primary small cell carcinoma of the breast differs from more common types of breast cancer in its biological features. It is anticipated that an improved understanding of the clinical characteristics of this tumor will result in the development of new therapeutic modalities, which would improve its prognosis.
Introduction
The extrapulmonary occurrence of small cell carcinoma was reported only recently (1) . Primary small cell carcinoma of the breast was first reported by Wade et al in 1983 (2) . An uncommon neoplasm, less than 40 cases of it have been reported in the literature, and neither its characteristics nor a standard course of therapy have been clearly defined (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . In the present report, we describe a case we treated and review and discuss the literature on this tumor, with a focus on its clinical characteristics and treatment.
Case report
A 33-year-old premenopausal Japanese woman presented with a right breast lump. Clinical examination revealed two firm mobile masses (4.0 x 3.5 cm and 2.5 x 2.0 cm) in the upper outer quadrant of the right breast. A contrast-enhanced MRI of her breast showed several enhanced masses in the right upper outer and central quadrants (Fig. 1) . A core needle biopsy was performed and the tumor was diagnosed as an invasive carcinoma. A right total mastectomy with axillary lymph nodes dissection (levels I-III) was performed. The pathological diagnosis was of small cell carcinoma. The tumor was composed of fairly uniform small dark cells disposed in nests and trabecular patterns, separated by bands of fibrous tissue. The cells had a high nucleocytoplasmic ratio, small hyperchromatic nuclei with inconspicuous nucleoli, scanty cytoplasm and poorly-defined cytoplasmic borders (Fig. 2 ). An immunohistochemical study showed that both estrogen (ER) and progesterone receptors (PgR) were negative, as was HER2 expression. Neuron-specific enolase (NSE) gave a positive reaction, and chromogranin and synaptophysin a negative one. No lymph node metastasis was found (0/41). The patient received four courses of epirubicin (60 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ) as postoperative adjuvant chemotherapy. Six months after surgery, MRI and an enhanced CT scan showed right parasternal lymph node recurrence (1.5 x 1.0 cm). The patient was treated with radiation (50 Gy) to the right chest wall, including the parasternal lymph nodes. The swollen lymph nodes decreased in size after radiation therapy and the patient is currently alive at 60 months after surgery.
Discussion
Primary small cell carcinoma of the breast is a rare tumor. A review of its clinicopathological characteristics in previous reports is summarized in Table I ( [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Women were affected in all cases but one (3), and the reported age of incidence was 33-75 years (average, 54.7). Tumor size ranged from 1.0 to 18 cm (mean, 4.4 cm). Although the frequency of vascular invasion and lymph node metastasis was, respectively, about 30 and 40% in the common phenotype of invasive ductal carcinoma, 71% (10/14) of patients had vascular invasion and 59% (19/32) axillary lymph node metastasis. Intraductal lesions were seen in 61% (19/31) of the tumors. The presence of an in situ component was a useful, but not indispensable, discovery for the diagnosis of primary mammary tumors (4, 10) . Table II summarizes our review of the immunohistochemical studies of previous reports. Regarding hormonal receptor findings, the positive ratio of ER was 27% (9/33) and of PgR 33% (9/27). Her2 overexpression was found in only 4.8% (1/21) of the reported cases. In general, the frequency of ER, PgR and HER2 overexpression was, Table I . Summary of clinicopathological findings in previously reported 1 primary small cell carcinoma of the breast. Table II . Summary of immunohistochemical studies in previously reported 1 primary small cell carcinoma of the breast. Table III . Summary of treatment and prognosis in previously reported primary small cell carcinoma of the breast. respectively, 60-70%, 50-60% and 20-30% in the common phenotype of invasive ductal carcinoma (22, 23) . Regarding the immunoreactivity of the neuroendocrine markers, the positive ratio of NSE, chromogranin and synaptophysin was 88% (30/34), 55% (17/31), and 60% (18/30), respectively. Diagnosis of these tumors was based on characteristic morphology, displayed by routine haematoxylin and eosin staining. It was found that the negative expression of neuroendocrine markers should not be used as an exclusion criterion (24) . However, the presence of positive neuroendocrine markers strongly supports a positive diagnosis (11) . Due to their rarity, a standard course of therapy for primary small cell carcinoma of the breast has yet to be established (11) . Although it seems logical that treatment of these tumors should be similar to that used for their pulmonary counterparts, most patients have been treated as standard cases of adenocarcinoma of the breast (Table III) . The main treatment modalities are surgery, chemotherapy and irradiation. Regarding the chemotherapeutic regimens employed in the literature, standard chemotherapy for the treatment of adenocarcinoma of the breast, such as anthracycline (doxorubicin or epirubicine) combination regimen and CMF (cyclophosphamide, methotrexate, 5-fluorouracil), was performed in 6 cases. In 5 cases, tamoxifen was also used. CDDP and etoposide (VP-16), which are often used for pulmonary small cell carcinoma, were administered to 6 patients. Recent studies have suggested that irinotecan (CPT-11) is a key drug in the treatment of pulmonary small cell carcinoma. In fact, a combination of CPT-11 and CDDP has been shown to be effective not only on pulmonary small cell carcinoma, but also on extrapulmonary small cell carcinoma such as esophageal small cell carcinoma (25) . This suggests that the CPT-11 and CDDP combination may prove to be an effective treatment for small cell carcinoma of the breast.
In the literature, disease recurrence was reported in 10 cases. These recurrent tumors were located in the lymph node alone in 2 cases, the distant organs in 5 cases, and in the lymph nodes and distant organs in 3 cases. According to previous reports, treatment of recurrent sites was uniformly unsuccessful (2, 3, 5, 7) . In the present report, the patient received a mastectomy and was administered postoperative adjuvant chemotherapy. In addition, radiotherapy was administered due to recurrence in the parasternal lymph nodes. As the recurrent site was localized, radiotherapy was effective for disease control and recurrence of the cancer has not been seen to date.
It has generally been thought that the prognosis for these tumors is equally as poor as it is for their counterparts in the lung (1,3,7) . However, recent reports (10, 20) , our case included, suggest that the prognosis would be better if such tumors were detected earlier, and that a combination therapy including surgery, chemotherapy and radiation may improve survival time. It is also expected that an improved understanding of the clinical characteristics of the tumor will result in the development of new therapeutic modalities, which would presumably improve patient outcome. 
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Bt, total mastectomy; Bp, partial mastectomy; Ch, chemotherapy; R, radiotherapy; VP-16, etoposide; CDV, cyclophosphamide, doxorubicin, vincristine; CMF, cyclophosphamide, methotrexate, 5-fluorouracil; FEC, 5-fluorouracil, epirubicine, cyclophosphamide; LN, lymph node; CNS, central nerve system; DOD, died of disease; DOC, died of other cause; NED, no evidence of disease; AWD, alive with disease; M, months.
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